Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Annals of Oncology

• Publication date

  2001-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1023/A:1013184301155PMID 11822753
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement.

  2000cited by this paper
• First line, non-hormonal treatment of women with HER2 overexpressing metastatic breast cancer with herceptin (trastuzumab, humanized anti-HER2 antibody)

  2000cited by this paper
• Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?

  2000cited by this paper
• Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.

  2000cited by this paper
• Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

  1999cited by this paper
• Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

  1999cited by this paper
• Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  1999cited by this paper
• Long-term weekly paclitaxel over 1 hour infusion with limited premedication. A phase II trial report

  1999cited by this paper
• Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase.

  1998cited by this paper
• Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

  1998cited by this paper
• Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.

  1998cited by this paper
• Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial

  1998cited by this paper
• In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product.

  1996cited by this paper
• Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

  1996cited by this paper
• A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines.

  1996cited by this paper
• Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.

  1996cited by this paper
• The microtubule-affecting drug paclitaxel has antiangiogenic activity.

  1996cited by this paper
• Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel.

  1996cited by this paper
• The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review.

  1995cited by this paper
• Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.

  1995cited by this paper
• Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

  1994cited by this paper
• Humanization of an anti-p185HER2 antibody for human cancer therapy.

  1992cited by this paper
• Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

  1991cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.

  1985cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Chemotherapy-induced Moderate to Severe Peripheral Neuropathy in Patients Receiving Adjuvant Radiotherapy for Breast Cancer

  2025cites this paper
• Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu.

  2021cites this paper
• Pulmonary Toxicities of Targeted Therapy

  2020cites this paper
• The Use of Trastuzumab in Metastatic Breast Cancer

  2019influential citation
• Conjugate of PAMAM Dendrimer, Doxorubicin and Monoclonal Antibody—Trastuzumab: The New Approach of a Well-Known Strategy

  2018cites this paper
• Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

  2016cites this paper
• The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patients with ovarian cancer

  2016cites this paper
• Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study

  2016cites this paper
• [Trastuzumab - a monoclonal antibody - and dendrimers in a targeted therapy for breast cancer].

  2015cites this paper
• Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies

  2015cites this paper
• Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires.

  2014cites this paper
• Paclitaxel and Trastuzumab for Breast Cancer

  2014cites this paper
• Model-Based Meta-Analysis for Quantifying Paclitaxel Dose Response in Cancer Patients

  2014cites this paper
• Cancer Chemotherapy Update Paclitaxel and Trastuzumab for Breast Cancer

  2014cites this paper
• Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.

  2014cites this paper
• Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial

  2013cites this paper
• A phase II study of ixabepilone and trastuzumab for metastatic HER 2-positive breast cancer

  2013cites this paper
• A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer.

  2013cites this paper
• Emerging evidence on the pathobiology of mucositis

  2013cites this paper
• Emerging evidence on the pathobiology of mucositis

  2013cites this paper
• Acute infusion reactions to chemotherapeutic drugs: a single institute experience.

  2013cites this paper
• Spotlight on Trastuzumab in the Management of HER2-Positive Metastatic and Early-Stage Breast Cancer

  2012cites this paper
• Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2

  2012cites this paper
• Oral Vinorelbine

  2012cites this paper
• Monoclonal Antibody-Based Targeted Therapy in Breast Cancer

  2012cites this paper
• Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines-a phase II multipractice study

  2012influential citation
• HER2 Targeted Therapy‐Induced Gastrointestinal Toxicity: From the Clinical Experience to Possible Molecular Mechanisms

  2012cites this paper
• Treatment of hormone receptor negative breast cancer

  2010cites this paper
• Fifteen-year trends in metastatic breast cancer survival in Greece

  2010cites this paper
• Biological therapy of breast cancer

  2009cites this paper
• NCCN task force report: management of neuropathy in cancer.

  2009cites this paper
• A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer

  2009cites this paper
• Monoclonal antibody therapy

  2009cites this paper
• Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study

  2009cites this paper
• A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer

  2009cites this paper
• Integration of Target-Based Agents in Current Protocols of Breast Cancer Therapy

  2009cites this paper
• Review Advances in systemic therapy for HER2-positive metastatic breast cancer

  2009cites this paper
• [Lapatinib treatment-option in trastuzumab-resistant breast cancer].

  2009cites this paper
• A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment

  2009cites this paper
• Use of trastuzumab in the treatment of metastatic breast cancer

  2009cites this paper
• LAPATINIB - KEZELÉSI LEHETŐSÉG TRASTUZUMAB-REZISZTENS EMLŐRÁKBAN

  2009cites this paper
• Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer

  2009cites this paper
• HER2 targeted therapies for cancer and the gastrointestinal tract.

  2009cites this paper
• Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy

  2009cites this paper
• HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies.

  2008cites this paper
• Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.

  2008cites this paper
• Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer

  2008cites this paper
• Prise en charge des cancers du sein métastatique HER2 surexprimé

  2007cites this paper
• Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer.

  2007cites this paper
• [Targeting ErbB receptors in breast cancer].

  2007cites this paper
• Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

  2007cites this paper
• Targeted therapy of breast cancer.

  2007cites this paper
• Progress and new standards of care in the management of HER-2 positive breast cancer.

  2007cites this paper
• Oral vinorelbine: role in the management of metastatic breast cancer.

  2007cites this paper
• Η έκφραση των υποδοχέων της τάξης HER στον καρκίνο του μαστού και βιολογική συμπεριφορά των καρκινικών κυττάρων

  2007cites this paper
• Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.

  2006cites this paper
• ERBB FAMILY IN BREAST CANCER: DETECTION METHODS, CLINICAL AND PROGNOSTIC SIGNIFICANCE, UNDER-RECOGNIZED MECHANISMS IN THEIR FUNCTION

  2006cites this paper
• Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy.

  2006cites this paper
• Breast cancer clinical practice recommendations from Saint-Paul-de-Vence: excerpts concerning targeted therapies

  2006cites this paper
• Targeting the HER Family of Receptors in the Treatment of Advanced Breast Cancer

  2006cites this paper
• Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions.

  2006cites this paper
• Recommandations pour la pratique clinique de Saint-Paul-de-Vence

  2005cites this paper
• Therapy of breast cancer with molecular targeting agents.

  2005cites this paper
• Monoclonal Antibody Strategies for Targeting HER2

  2005cites this paper
• Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

  2005cites this paper
• Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer.

  2005cites this paper
• Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.

  2005cites this paper
• Liver metastases from breast cancer: management of patients with significant liver dysfunction.

  2005cites this paper
• Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate.

  2005cites this paper
• Neurotoxicity of taxanes: Symptoms and quality of life assessment

  2004cites this paper
• Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer

  2004cites this paper
• Locally advanced breast cancer in octogenarian women

  2004influential citation
• Maximizing clinical benefit with trastuzumab.

  2004cites this paper
• Trastuzumab-based combination therapy for breast cancer

  2004cites this paper
• Paclitaxel and Gemcitabine, As First-Line Chemotherapy, Combined with Trastuzumab in Patients with Advanced Breast Cancer: A Phase II Study Conducted by the Hellenic Cooperative Oncology Group (HeCOG)

  2004cites this paper
• Taxanes in elderly breast cancer patients.

  2004cites this paper
• Efficacy and safety of trastuzumab

  2004cites this paper
• Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

  2004cites this paper
• Endothelial cell effects of cytotoxics: balance between desired and unwanted effects.

  2004cites this paper
• Trastuzumab and docetaxel for metastatic breast cancer: an experience from a cancer centre in India.

  2004cites this paper
• Continuation of Trastuzumab Beyond Disease Progression: More Questions Than Answers

  2004cites this paper
• Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer.

  2003cites this paper
• Weekly Paclitaxel (Taxol®) with or without Trastuzumab (Herceptin®) in Advanced Breast Cancer: A Community-Based Observation Study

  2003cites this paper
• Trastuzumab in Combination with Chemotherapy

  2003cites this paper
• Trastuzumab-based combinations in metastatic breast cancer: how to make a choice.

  2003cites this paper
• Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.

  2003cites this paper
• Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.

  2003cites this paper
• Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay

  2003cites this paper
• An investigation of the role of the ErbB receptor family in chemotherapeutic drug resistance and invasion in human breast cancer

  2002cites this paper